Medicortex International AB (publ) (NGM:MEDFIN)
Sweden · Delayed Price · Currency is SEK 1.310
+0.110 (9.17%)
At close: Oct 5, 2026
NGM:MEDFIN Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.2 | 4.92 | 7.15 | 18.69 | 15.48 | 16.95 | |
Revenue Growth | -59.92% | -31.21% | -61.76% | 20.70% | -8.67% | 60.85% |
Cost of Revenue | 1.27 | 2.46 | 3.18 | 8.8 | 6.95 | 6.82 |
Gross Profit | 0.93 | 2.45 | 3.97 | 9.88 | 8.54 | 10.13 |
Selling, General & Admin | 7.9 | 7.62 | 8.99 | 17.02 | 16.85 | 13.35 |
Other Operating Expenses | -12.85 | -0.01 | 0.12 | -0.7 | -3.68 | -0.38 |
Operating Expenses | -4.54 | 8.32 | 10.89 | 17.94 | 14.14 | 13.86 |
Operating Income | 5.46 | -5.87 | -6.92 | -8.06 | -5.6 | -3.73 |
Interest Expense | -0.39 | -0.58 | -1.08 | -1.37 | -0.21 | -0.14 |
Interest & Investment Income | 0.02 | 0.01 | 0.03 | 0.01 | 0 | 0 |
Earnings From Equity Investments | -3.27 | -3.12 | -26.1 | -14.72 | 2.62 | 0.57 |
Other Non Operating Income (Expenses) | -0 | - | -0 | -0 | - | -0 |
Pretax Income | 1.83 | -9.56 | -34.07 | -24.14 | -3.19 | -3.29 |
Income Tax Expense | - | - | 0 | 0.31 | - | 0.3 |
Earnings From Continuing Operations | 1.83 | -9.56 | -34.08 | -24.45 | -3.19 | -3.6 |
Minority Interest in Earnings | - | - | 0.94 | 2.01 | 2.13 | 0.38 |
Net Income | 1.83 | -9.56 | -33.14 | -22.44 | -1.06 | -3.21 |
Net Income to Common | 1.83 | -9.56 | -33.14 | -22.44 | -1.06 | -3.21 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3 | 2 | 2 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 3 | 2 | 2 | 0 | 0 | 0 |
Shares Change | 43.68% | 11.05% | 1671.67% | 37.66% | 38.12% | 29.31% |
EPS (Basic) | 0.58 | -3.90 | -15.03 | -180.33 | -11.72 | -49.08 |
EPS (Diluted) | 0.58 | -3.90 | -15.03 | -180.33 | -11.72 | -49.08 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.74 | -3.98 | -8.66 | -11.59 | -4.79 | 0.11 |
Free Cash Flow Per Share | -0.86 | -1.63 | -3.93 | -93.11 | -53.02 | 1.64 |
Gross Margin | 42.14% | 49.87% | 55.54% | 52.89% | 55.14% | 59.75% |
Operating Margin | 248.46% | -119.29% | -96.79% | -43.11% | -36.19% | -21.98% |
Profit Margin | 83.25% | -194.40% | -463.61% | -120.09% | -6.84% | -18.95% |
Free Cash Flow Margin | -124.61% | -80.96% | -121.14% | -62.01% | -30.95% | 0.63% |
EBITDA | 5.6 | -5.44 | -5.4 | -7.07 | -5.16 | -3.31 |
EBITDA Margin | 254.54% | -110.65% | -75.59% | -37.83% | -33.34% | -19.52% |
D&A For EBITDA | 0.13 | 0.42 | 1.52 | 0.99 | 0.44 | 0.42 |
EBIT | 5.46 | -5.87 | -6.92 | -8.06 | -5.6 | -3.73 |
EBIT Margin | 248.46% | -119.29% | -96.79% | -43.11% | -36.19% | -21.98% |
Revenue as Reported | 15.05 | 4.93 | 7.03 | 19.66 | 19.21 | 17.35 |